Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi US

www.sanofi.us

Latest From Sanofi US

Supreme Court Declines ‘Skinny Label’ Case, But Teva To Continue Fight In District Court

Justice Kavanaugh voted to grant Teva’s petition for certiorari. It is unknown if other justices voted with him. The high court last month declined to hear Novartis's Gilenya patent case and Sanofi’s antitrust allegations against Mylan’s EpiPen rebate agreements.

Generic Drugs Intellectual Property

HHS Officials Raise Concerns About Pricing, Patent Restrictions for Medical Countermeasures

US FDA Commissioner and Health and Human Services Assistant Secretary for Preparedness and Response cautioned against changes to rewards for medical countermeasure developers in the next Pandemic and All-Hazards Preparedness Act reauthorization that might discourage biotech companies from working with the government.

Legislation Pricing Debate

Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale

Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.

Reimbursement Pricing Strategies

Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale

Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.

Reimbursement Pricing Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register